(SIGA) SIGA Technologies - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US8269171067
Stock: Antiviral, Smallpox Treatment, TPOXX, Health Security
Total Rating 52
Risk 92
Buy Signal -0.32
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 10.42% |
| Yield on Cost 5y | 12.63% |
| Yield CAGR 5y | 10.06% |
| Payout Consistency | 98.0% |
| Payout Ratio | 1.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 56.6% |
| Relative Tail Risk | -10.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.59 |
| Alpha | 12.95 |
| Character TTM | |
|---|---|
| Beta | 0.641 |
| Beta Downside | 0.268 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.39% |
| CAGR/Max DD | 0.14 |
Description: SIGA SIGA Technologies December 27, 2025
SIGA Technologies, Inc. (NASDAQ: SIGA) is a commercial-stage biotech focused on the U.S. health-security market, best known for its FDA-approved antiviral TPOXX (tecovirimat) for smallpox treatment. Founded in 1995 and based in New York, the company operates as a common-stock listed under the Pharmaceuticals GICS sub-industry.
As of its FY 2023 filing, SIGA reported $85 million in total revenue, with TPOXX accounting for roughly 70 % of sales, and held $210 million in cash and short-term investments, providing a runway of over three years without external financing. The firm benefits from a stable government contract pipeline-particularly the U.S. Strategic National Stockpile-while broader sector drivers include heightened biodefense spending, which grew at a 6 % CAGR in the past five years.
For a deeper, data-driven view of SIGA’s valuation metrics and risk profile, consider exploring the analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 74.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.50 > 0.02 and ΔFCF/TA 13.64 > 1.0 |
| NWC/Revenue: 117.8% < 20% (prev 91.17%; Δ 26.63% < -1%) |
| CFO/TA 0.50 > 3% & CFO 116.6m > Net Income 74.5m |
| Net Debt (-171.0m) to EBITDA (94.3m): -1.81 < 3 |
| Current Ratio: 9.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.6m) vs 12m ago -0.23% < -2% |
| Gross Margin: 76.29% > 18% (prev 0.78%; Δ 7550 % > 0.5%) |
| Asset Turnover: 80.69% > 50% (prev 88.93%; Δ -8.24% > 0%) |
| Interest Coverage Ratio: -29.47 > 6 (EBITDA TTM 94.3m / Interest Expense TTM -3.18m) |
Altman Z'' 6.76
| A: 0.88 (Total Current Assets 227.7m - Total Current Liabilities 24.8m) / Total Assets 231.6m |
| B: -0.16 (Retained Earnings -37.6m / Total Assets 231.6m) |
| C: 0.44 (EBIT TTM 93.7m / Avg Total Assets 213.5m) |
| D: -1.34 (Book Value of Equity -37.6m / Total Liabilities 28.1m) |
| Altman-Z'' Score: 6.76 = AAA |
Beneish M -4.00
| DSRI: 0.21 (Receivables 2.49m/12.1m, Revenue 172.2m/173.7m) |
| GMI: 1.03 (GM 76.29% / 78.34%) |
| AQI: 0.17 (AQ_t 0.01 / AQ_t-1 0.07) |
| SGI: 0.99 (Revenue 172.2m / 173.7m) |
| TATA: -0.18 (NI 74.5m - CFO 116.6m) / TA 231.6m) |
| Beneish M-Score: -4.34 (Cap -4..+1) = AAA |
What is the price of SIGA shares?
As of February 10, 2026, the stock is trading at USD 6.53 with a total of 237,063 shares traded.
Over the past week, the price has changed by -6.04%, over one month by -1.21%, over three months by +0.31% and over the past year by +18.80%.
Over the past week, the price has changed by -6.04%, over one month by -1.21%, over three months by +0.31% and over the past year by +18.80%.
Is SIGA a buy, sell or hold?
SIGA Technologies has no consensus analysts rating.
What are the forecasts/targets for the SIGA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.5 | 168.5% |
| Analysts Target Price | 17.5 | 168.5% |
| ValueRay Target Price | 7.5 | 14.5% |
SIGA Fundamental Data Overview February 03, 2026
P/E Trailing = 6.6337
P/E Forward = 4.5106
P/S = 2.7855
P/B = 2.3967
Revenue TTM = 172.2m USD
EBIT TTM = 93.7m USD
EBITDA TTM = 94.3m USD
Long Term Debt = 582.7k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 582.7k USD (from shortTermDebt, last quarter)
Debt = 914.5k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -171.0m USD (from netDebt column, last quarter)
Enterprise Value = 308.8m USD (479.8m + Debt 914.5k - CCE 172.0m)
Interest Coverage Ratio = -29.47 (Ebit TTM 93.7m / Interest Expense TTM -3.18m)
EV/FCF = 2.65x (Enterprise Value 308.8m / FCF TTM 116.3m)
FCF Yield = 37.67% (FCF TTM 116.3m / Enterprise Value 308.8m)
FCF Margin = 67.52% (FCF TTM 116.3m / Revenue TTM 172.2m)
Net Margin = 43.23% (Net Income TTM 74.5m / Revenue TTM 172.2m)
Gross Margin = 76.29% ((Revenue TTM 172.2m - Cost of Revenue TTM 40.8m) / Revenue TTM)
Gross Margin QoQ = 61.75% (prev 68.50%)
Tobins Q-Ratio = 1.33 (Enterprise Value 308.8m / Total Assets 231.6m)
Interest Expense / Debt = 97.38% (Interest Expense 890.6k / Debt 914.5k)
Taxrate = 22.16% (16.9m / 76.1m)
NOPAT = 73.0m (EBIT 93.7m * (1 - 22.16%))
Current Ratio = 9.17 (Total Current Assets 227.7m / Total Current Liabilities 24.8m)
Debt / Equity = 0.00 (Debt 914.5k / totalStockholderEquity, last quarter 203.5m)
Debt / EBITDA = -1.81 (Net Debt -171.0m / EBITDA 94.3m)
Debt / FCF = -1.47 (Net Debt -171.0m / FCF TTM 116.3m)
Total Stockholder Equity = 211.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 34.88% (Net Income 74.5m / Total Assets 231.6m)
RoE = 35.26% (Net Income TTM 74.5m / Total Stockholder Equity 211.2m)
RoCE = 44.27% (EBIT 93.7m / Capital Employed (Equity 211.2m + L.T.Debt 582.7k))
RoIC = 34.55% (NOPAT 73.0m / Invested Capital 211.2m)
WACC = 8.26% (E(479.8m)/V(480.7m) * Re(8.28%) + (debt cost/tax rate unavailable))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.36%
[DCF Debug] Terminal Value 80.40% ; FCFF base≈98.4m ; Y1≈121.3m ; Y5≈206.7m
Fair Price DCF = 48.68 (EV 3.31b - Net Debt -171.0m = Equity 3.49b / Shares 71.6m; r=8.26% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -10.74 | EPS CAGR: -78.27% | SUE: -0.51 | # QB: 0
Revenue Correlation: -24.84 | Revenue CAGR: -63.55% | SUE: 0.44 | # QB: 0
EPS next Year (2026-12-31): EPS=1.51 | Chg30d=-0.080 | Revisions Net=-1 | Growth EPS=+297.4% | Growth Revenue=+132.4%
P/E Forward = 4.5106
P/S = 2.7855
P/B = 2.3967
Revenue TTM = 172.2m USD
EBIT TTM = 93.7m USD
EBITDA TTM = 94.3m USD
Long Term Debt = 582.7k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 582.7k USD (from shortTermDebt, last quarter)
Debt = 914.5k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -171.0m USD (from netDebt column, last quarter)
Enterprise Value = 308.8m USD (479.8m + Debt 914.5k - CCE 172.0m)
Interest Coverage Ratio = -29.47 (Ebit TTM 93.7m / Interest Expense TTM -3.18m)
EV/FCF = 2.65x (Enterprise Value 308.8m / FCF TTM 116.3m)
FCF Yield = 37.67% (FCF TTM 116.3m / Enterprise Value 308.8m)
FCF Margin = 67.52% (FCF TTM 116.3m / Revenue TTM 172.2m)
Net Margin = 43.23% (Net Income TTM 74.5m / Revenue TTM 172.2m)
Gross Margin = 76.29% ((Revenue TTM 172.2m - Cost of Revenue TTM 40.8m) / Revenue TTM)
Gross Margin QoQ = 61.75% (prev 68.50%)
Tobins Q-Ratio = 1.33 (Enterprise Value 308.8m / Total Assets 231.6m)
Interest Expense / Debt = 97.38% (Interest Expense 890.6k / Debt 914.5k)
Taxrate = 22.16% (16.9m / 76.1m)
NOPAT = 73.0m (EBIT 93.7m * (1 - 22.16%))
Current Ratio = 9.17 (Total Current Assets 227.7m / Total Current Liabilities 24.8m)
Debt / Equity = 0.00 (Debt 914.5k / totalStockholderEquity, last quarter 203.5m)
Debt / EBITDA = -1.81 (Net Debt -171.0m / EBITDA 94.3m)
Debt / FCF = -1.47 (Net Debt -171.0m / FCF TTM 116.3m)
Total Stockholder Equity = 211.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 34.88% (Net Income 74.5m / Total Assets 231.6m)
RoE = 35.26% (Net Income TTM 74.5m / Total Stockholder Equity 211.2m)
RoCE = 44.27% (EBIT 93.7m / Capital Employed (Equity 211.2m + L.T.Debt 582.7k))
RoIC = 34.55% (NOPAT 73.0m / Invested Capital 211.2m)
WACC = 8.26% (E(479.8m)/V(480.7m) * Re(8.28%) + (debt cost/tax rate unavailable))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.36%
[DCF Debug] Terminal Value 80.40% ; FCFF base≈98.4m ; Y1≈121.3m ; Y5≈206.7m
Fair Price DCF = 48.68 (EV 3.31b - Net Debt -171.0m = Equity 3.49b / Shares 71.6m; r=8.26% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -10.74 | EPS CAGR: -78.27% | SUE: -0.51 | # QB: 0
Revenue Correlation: -24.84 | Revenue CAGR: -63.55% | SUE: 0.44 | # QB: 0
EPS next Year (2026-12-31): EPS=1.51 | Chg30d=-0.080 | Revisions Net=-1 | Growth EPS=+297.4% | Growth Revenue=+132.4%